How many insider trades does FilingIQ track for BDTX?

FilingIQ tracks 550 Form 4 insider transactions for BDTX (Black Diamond Therapeutics, Inc.), covering filings from Feb 3, 2020 onwards. 2 of those were filed in the last 90 days.

Are BDTX insiders net buyers or net sellers?

Across the full Form 4 history for BDTX, 35 transactions (6%) were open-market purchases and 190 (35%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does BDTX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is BDTX in?

Black Diamond Therapeutics, Inc. (BDTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $120.22M.

BDTX insider trading

NasdaqGS Healthcare

Black Diamond Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

550

Last 90 days

Buys / sells

6% / 35%

Market cap

$120.22M

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Company website: www.blackdiamondtherapeutics.com

BDTX insider activity at a glance

FilingIQ has scored 550 insider transactions for BDTX since Feb 3, 2020. The most recent filing in our index is dated Mar 20, 2026.

Across the full history, 35 open-market purchases and 190 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on BDTX insider trades is 50.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live BDTX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for BDTX?: FilingIQ tracks 550 Form 4 insider transactions for BDTX (Black Diamond Therapeutics, Inc.), covering filings from Feb 3, 2020 onwards. 2 of those were filed in the last 90 days.
Are BDTX insiders net buyers or net sellers?: Across the full Form 4 history for BDTX, 35 transactions (6%) were open-market purchases and 190 (35%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does BDTX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is BDTX in?: Black Diamond Therapeutics, Inc. (BDTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $120.22M.

Methodology & sources

Every BDTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.